Aclarion, Inc. (NASDAQ:ACON) Sees Large Growth in Short Interest

Aclarion, Inc. (NASDAQ:ACON) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 62,000 shares, a growth of 9.3% from the March 15th total of 56,700 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average trading volume of 1,890,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Aclarion

A hedge fund recently bought a new stake in Aclarion stock. Captrust Financial Advisors purchased a new position in Aclarion, Inc. (NASDAQ:ACON) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 78,400 shares of the company’s stock, valued at approximately $61,000. Captrust Financial Advisors owned 1.00% of Aclarion as of its most recent SEC filing. 7.52% of the stock is owned by institutional investors.

Aclarion Price Performance

Shares of ACON stock opened at $0.31 on Tuesday. The stock has a fifty day moving average of $0.73 and a 200 day moving average of $3.23. Aclarion has a 52 week low of $0.27 and a 52 week high of $37.92.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.